Skip to content

Study · Systematic review · 2017

2 results

Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.

Singh S, Wright EE Jr, Kwan AY, Thompson JC, Syed IA, Korol EE, Waser NA, Yu MB, Juneja R

Diabetes, obesity & metabolism5 Dec 2016Cited by 84 (Europe PMC)

PMID27717130 (opens in a new tab)PMCIDPMC5299485 (opens in a new tab)DOI10.1111/dom.12805 (opens in a new tab)PepBankPUB-27717130
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes inadequately controlled on oral drugs, once-daily liraglutide did not reduce HbA1c more than basal insulin.

    In plain wordsIn adults with type 2 diabetes, once-daily liraglutide did not lower HbA1c more than basal insulin did.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c reduction versus basal insulin
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c difference
    0.06%
    liraglutide vs basal insulin

    Source sentences

    Summary
    whilst once-daily liraglutide and twice-daily exenatide did not (liraglutide: 0.06% [-0.06, 0.18]
    1 context sentence
    Summary · context
    Randomized clinical trials (RCTs) of ≥16 weeks' duration comparing GLP-1 RAs vs basal insulins in adults with type 2 diabetes inadequately controlled with oral antihyperglycemic drugs were included.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, all GLP-1 receptor agonists (including liraglutide) reduced mean weight while basal insulins increased it.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group led to weight loss while basal insulins led to weight gain.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Mean weight reduction was seen with all GLP-1 RAs while mean weight gain was seen with basal insulins.
    1 context sentence
    Summary · context
    Randomized clinical trials (RCTs) of ≥16 weeks' duration comparing GLP-1 RAs vs basal insulins in adults with type 2 diabetes inadequately controlled with oral antihyperglycemic drugs were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase not statedNCT03959865

GLP-1 REceptor Agonists and Real World EvIdeNce

University of Padovan = 6,00019 Dec 2018 to est. 31 May 2019

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 22 May 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.